Related Experiment Video
Updated: Jan 28, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Phenotypic and Genotypic Characterization of ESBL- and Carbapenemase-producing Escherichia coli Isolates in Irritable
Anis Ramezani1, Mohammad Yazdanmanesh2, Hamid Heidari3
1Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Introduction:
The prevalence of irritable bowel syndrome (IBS) is estimated to range from 10% to 20%. The symptoms of IBS have been associated with an increased presence of Escherichia coli bacteria in the bowel. Treatment is often complicated by the growing prevalence of antibioticresistant strains, particularly those producing extended-spectrum β-lactamases (ESBLs) and carbapenemases. Given the clinical significance of antibiotic resistance in E. coli among IBS patients, this study aimed to investigate the phenotypic and genotypic characteristics of ESBL- and carbapenemase-producing E. coli isolates.
Methods:
The isolates were obtained from stool samples of IBS patients and identified using conventional biochemical methods. Phenotypic tests were conducted to detect ESBL- and carbapenemaseproducing strains. Polymerase chain reaction (PCR) was employed to identify genes associated with ESBL and carbapenemase production. Additionally, biofilm formation was assessed using a microtiter plate assay.
Results:
A total of 67 E. coli isolates were recovered from patients. Of these, 37 (55.2%) were phenotypically positive for ESBL or carbapenemase production. PCR analysis revealed that 18 isolates (26.9%) harbored at least one ESBL gene, while 16 (23.9%) carried at least one carbapenemaserelated gene. The most prevalent ESBL gene was blaTEM (23.9%), while blaOXA-23 and blaKPC were the most common carbapenemase genes (each found in 10.4% of isolates). Notably, all isolates exhibited biofilm-forming ability, with nearly half (49.25%) forming strong biofilms.
Conclusion:
The notable prevalence of ESBL- and carbapenemase-producing E. coli among IBS patients may significantly affect patient outcomes, underscoring the need for targeted antibiotic stewardship and monitoring of biofilm-forming, drug-resistant strains.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...